Q2 2025 OraSure Technologies Inc Earnings Call Transcript
Key Points
- OraSure Technologies Inc (OSUR) reported Q2 revenue in the top half of their guidance range for both total and core revenue.
- The company launched the HEMAcollect PROTEIN offering, expanding their sample management solutions into blood sample types.
- OraSure Technologies Inc (OSUR) completed the transition from external contract manufacturing to internal capabilities ahead of schedule, which is expected to improve operating efficiencies.
- The company renewed its agreement with gene Dx and established a new relationship with targeted genomics, expanding its customer base.
- OraSure Technologies Inc (OSUR) has a strong balance sheet with zero debt and $235 million in cash and cash equivalents.
- Sample management revenue decreased by 22% year over year, primarily due to a decline from a large customer in the consumer genetics segment.
- International orders for HIV tests are expected to slow in the second half of the year due to USAID funding freezes.
- The Together Take Me Home program faces uncertainty in funding, impacting expected revenue in Q3.
- The company reported a GAAP operating loss of $18 million and a non-GAAP operating loss of $13.2 million in Q2.
- There is continued disruption in ordering patterns from a significant consumer genetics customer, with no significant revenue expected from them in the second half of the year.
Good day, and thank you for standing by. Welcome to the OraSure Technology second quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I'd now like to hand the conference over to Jason Plagman, Vice President of Investor relations. Please go ahead.
Good afternoon, and welcome to OraSure Technologies second quarter 2025 earnings call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website.
Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share, and other financial performance, product development, performance, shipments and markets, business plans,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
